COHEN & STEERS INC (CNS) Fundamental Analysis & Valuation

NYSE:CNS • US19247A1007

Current stock price

64.51 USD
+1.35 (+2.14%)
At close:
64.51 USD
0 (0%)
After Hours:

This CNS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. CNS Profitability Analysis

1.1 Basic Checks

  • CNS had positive earnings in the past year.
  • In the past year CNS has reported a negative cash flow from operations.
  • Each year in the past 5 years CNS has been profitable.
  • Of the past 5 years CNS 4 years had a positive operating cash flow.
CNS Yearly Net Income VS EBIT VS OCF VS FCFCNS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M

1.2 Ratios

  • CNS has a Return On Assets of 17.48%. This is amongst the best in the industry. CNS outperforms 96.25% of its industry peers.
  • With an excellent Return On Equity value of 27.27%, CNS belongs to the best of the industry, outperforming 92.08% of the companies in the same industry.
  • CNS has a better Return On Invested Capital (20.96%) than 97.08% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for CNS is significantly above the industry average of 7.19%.
Industry RankSector Rank
ROA 17.48%
ROE 27.27%
ROIC 20.96%
ROA(3y)17.87%
ROA(5y)24.39%
ROE(3y)30.23%
ROE(5y)44.84%
ROIC(3y)23.28%
ROIC(5y)32.89%
CNS Yearly ROA, ROE, ROICCNS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60 80

1.3 Margins

  • Looking at the Profit Margin, with a value of 27.66%, CNS is in the better half of the industry, outperforming 71.25% of the companies in the same industry.
  • In the last couple of years the Profit Margin of CNS has grown nicely.
  • With a decent Operating Margin value of 31.68%, CNS is doing good in the industry, outperforming 60.83% of the companies in the same industry.
  • CNS's Operating Margin has declined in the last couple of years.
  • The Gross Margin of CNS (86.84%) is better than 92.08% of its industry peers.
  • In the last couple of years the Gross Margin of CNS has remained more or less at the same level.
Industry RankSector Rank
OM 31.68%
PM (TTM) 27.66%
GM 86.84%
OM growth 3Y-4.66%
OM growth 5Y-2.01%
PM growth 3Y-3.48%
PM growth 5Y8.65%
GM growth 3Y0.67%
GM growth 5Y0.08%
CNS Yearly Profit, Operating, Gross MarginsCNS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. CNS Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, CNS has more shares outstanding
  • CNS has more shares outstanding than it did 5 years ago.
  • CNS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CNS Yearly Shares OutstandingCNS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M
CNS Yearly Total Debt VS Total AssetsCNS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

2.2 Solvency

  • CNS has an Altman-Z score of 7.31. This indicates that CNS is financially healthy and has little risk of bankruptcy at the moment.
  • CNS's Altman-Z score of 7.31 is amongst the best of the industry. CNS outperforms 92.92% of its industry peers.
  • There is no outstanding debt for CNS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 7.31
ROIC/WACCN/A
WACCN/A
CNS Yearly LT Debt VS Equity VS FCFCNS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M

2.3 Liquidity

  • CNS has a Current Ratio of 0.98. This is a bad value and indicates that CNS is not financially healthy enough and could expect problems in meeting its short term obligations.
  • CNS has a Current ratio (0.98) which is in line with its industry peers.
  • CNS has a Quick Ratio of 0.98. This is a bad value and indicates that CNS is not financially healthy enough and could expect problems in meeting its short term obligations.
  • CNS has a Quick ratio of 0.98. This is comparable to the rest of the industry: CNS outperforms 43.33% of its industry peers.
Industry RankSector Rank
Current Ratio 0.98
Quick Ratio 0.98
CNS Yearly Current Assets VS Current LiabilitesCNS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. CNS Growth Analysis

3.1 Past

  • The Earnings Per Share has been growing slightly by 5.80% over the past year.
  • Measured over the past 5 years, CNS shows a small growth in Earnings Per Share. The EPS has been growing by 3.74% on average per year.
  • The Revenue has been growing slightly by 7.04% in the past year.
  • The Revenue has been growing slightly by 5.73% on average over the past years.
EPS 1Y (TTM)5.8%
EPS 3Y-5.81%
EPS 5Y3.74%
EPS Q2Q%3.85%
Revenue 1Y (TTM)7.04%
Revenue growth 3Y-0.12%
Revenue growth 5Y5.73%
Sales Q2Q%17.21%

3.2 Future

  • Based on estimates for the next years, CNS will show a quite strong growth in Earnings Per Share. The EPS will grow by 8.66% on average per year.
  • Based on estimates for the next years, CNS will show a small growth in Revenue. The Revenue will grow by 6.70% on average per year.
EPS Next Y10.23%
EPS Next 2Y10.78%
EPS Next 3Y3.87%
EPS Next 5Y8.66%
Revenue Next Year3.84%
Revenue Next 2Y4.21%
Revenue Next 3Y-0.11%
Revenue Next 5Y6.7%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
CNS Yearly Revenue VS EstimatesCNS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M 800M
CNS Yearly EPS VS EstimatesCNS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 1 2 3 4 5

More info and screens

Find the best growth stocksShow best growing peers

3

4. CNS Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 20.81 indicates a rather expensive valuation of CNS.
  • 63.33% of the companies in the same industry are cheaper than CNS, based on the Price/Earnings ratio.
  • The average S&P500 Price/Earnings ratio is at 27.18. CNS is valued slightly cheaper when compared to this.
  • Based on the Price/Forward Earnings ratio of 18.88, the valuation of CNS can be described as rather expensive.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of CNS is on the same level as its industry peers.
  • CNS is valuated cheaply when we compare the Price/Forward Earnings ratio to 37.96, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 20.81
Fwd PE 18.88
CNS Price Earnings VS Forward Price EarningsCNS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of CNS indicates a somewhat cheap valuation: CNS is cheaper than 75.42% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 16.56
CNS Per share dataCNS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8 10

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • The decent profitability rating of CNS may justify a higher PE ratio.
PEG (NY)2.03
PEG (5Y)5.56
EPS Next 2Y10.78%
EPS Next 3Y3.87%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

5

5. CNS Dividend Analysis

5.1 Amount

  • With a Yearly Dividend Yield of 4.18%, CNS is a good candidate for dividend investing.
  • Compared to an average industry Dividend Yield of 6.65, CNS has a dividend in line with its industry peers.
  • Compared to an average S&P500 Dividend Yield of 1.82, CNS pays a better dividend.
Industry RankSector Rank
Dividend Yield 4.18%

5.2 History

  • The dividend of CNS decreases each year by -0.61%.
  • CNS has paid a dividend for at least 10 years, which is a reliable track record.
  • CNS has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)-0.61%
Div Incr Years3
Div Non Decr Years3
CNS Yearly Dividends per shareCNS Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 1 2 3

5.3 Sustainability

  • CNS pays out 82.84% of its income as dividend. This is not a sustainable payout ratio.
DP82.84%
EPS Next 2Y10.78%
EPS Next 3Y3.87%
CNS Yearly Income VS Free CF VS DividendCNS Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M
CNS Dividend Payout.CNS Dividend Payout, showing the Payout Ratio.CNS Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

CNS Fundamentals: All Metrics, Ratios and Statistics

COHEN & STEERS INC

NYSE:CNS (4/13/2026, 6:40:00 PM)

After market: 64.51 0 (0%)

64.51

+1.35 (+2.14%)

Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryCapital Markets
Earnings (Last)01-22
Earnings (Next)04-16
Inst Owners56.08%
Inst Owner Change0.01%
Ins Owners22.61%
Ins Owner Change5.68%
Market Cap3.32B
Revenue(TTM)553.87M
Net Income(TTM)153.22M
Analysts48
Price Target66.3 (2.77%)
Short Float %5.07%
Short Ratio3.83
Dividend
Industry RankSector Rank
Dividend Yield 4.18%
Yearly Dividend2.5
Dividend Growth(5Y)-0.61%
DP82.84%
Div Incr Years3
Div Non Decr Years3
Ex-Date03-09
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.25%
Min EPS beat(2)-0.99%
Max EPS beat(2)3.48%
EPS beat(4)1
Avg EPS beat(4)-1.02%
Min EPS beat(4)-4.27%
Max EPS beat(4)3.48%
EPS beat(8)2
Avg EPS beat(8)-1.07%
EPS beat(12)4
Avg EPS beat(12)0.08%
EPS beat(16)8
Avg EPS beat(16)0.68%
Revenue beat(2)1
Avg Revenue beat(2)0.17%
Min Revenue beat(2)-0.52%
Max Revenue beat(2)0.85%
Revenue beat(4)2
Avg Revenue beat(4)0.26%
Min Revenue beat(4)-1.18%
Max Revenue beat(4)1.91%
Revenue beat(8)3
Avg Revenue beat(8)-0.96%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-7.8%
PT rev (3m)-15.58%
EPS NQ rev (1m)3.85%
EPS NQ rev (3m)-0.61%
EPS NY rev (1m)1.3%
EPS NY rev (3m)-0.69%
Revenue NQ rev (1m)1.94%
Revenue NQ rev (3m)-1.93%
Revenue NY rev (1m)-3.21%
Revenue NY rev (3m)-5.27%
Valuation
Industry RankSector Rank
PE 20.81
Fwd PE 18.88
P/S 5.99
P/FCF N/A
P/OCF N/A
P/B 5.9
P/tB 6.12
EV/EBITDA 16.56
EPS(TTM)3.1
EY4.81%
EPS(NY)3.42
Fwd EY5.3%
FCF(TTM)-2.46
FCFYN/A
OCF(TTM)-2.34
OCFYN/A
SpS10.78
BVpS10.94
TBVpS10.55
PEG (NY)2.03
PEG (5Y)5.56
Graham Number27.62
Profitability
Industry RankSector Rank
ROA 17.48%
ROE 27.27%
ROCE 27.12%
ROIC 20.96%
ROICexc 27.04%
ROICexgc 30.2%
OM 31.68%
PM (TTM) 27.66%
GM 86.84%
FCFM N/A
ROA(3y)17.87%
ROA(5y)24.39%
ROE(3y)30.23%
ROE(5y)44.84%
ROIC(3y)23.28%
ROIC(5y)32.89%
ROICexc(3y)33.62%
ROICexc(5y)61.08%
ROICexgc(3y)38.82%
ROICexgc(5y)75.29%
ROCE(3y)30.11%
ROCE(5y)42.55%
ROICexgc growth 3Y-33.24%
ROICexgc growth 5Y-15.16%
ROICexc growth 3Y-30.82%
ROICexc growth 5Y-13.86%
OM growth 3Y-4.66%
OM growth 5Y-2.01%
PM growth 3Y-3.48%
PM growth 5Y8.65%
GM growth 3Y0.67%
GM growth 5Y0.08%
F-Score3
Asset Turnover0.63
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA 0
Cap/Depr 51.04%
Cap/Sales 1.08%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.98
Quick Ratio 0.98
Altman-Z 7.31
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)421.2%
Cap/Depr(5y)277.41%
Cap/Sales(3y)4.98%
Cap/Sales(5y)3.23%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)5.8%
EPS 3Y-5.81%
EPS 5Y3.74%
EPS Q2Q%3.85%
EPS Next Y10.23%
EPS Next 2Y10.78%
EPS Next 3Y3.87%
EPS Next 5Y8.66%
Revenue 1Y (TTM)7.04%
Revenue growth 3Y-0.12%
Revenue growth 5Y5.73%
Sales Q2Q%17.21%
Revenue Next Year3.84%
Revenue Next 2Y4.21%
Revenue Next 3Y-0.11%
Revenue Next 5Y6.7%
EBIT growth 1Y1.51%
EBIT growth 3Y-4.78%
EBIT growth 5Y3.6%
EBIT Next Year0.51%
EBIT Next 3Y0.2%
EBIT Next 5Y11.96%
FCF growth 1Y-248.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-224.57%
OCF growth 3YN/A
OCF growth 5YN/A

COHEN & STEERS INC / CNS Fundamental Analysis FAQ

What is the ChartMill fundamental rating of COHEN & STEERS INC (CNS) stock?

ChartMill assigns a fundamental rating of 5 / 10 to CNS.


What is the valuation status for CNS stock?

ChartMill assigns a valuation rating of 2 / 10 to COHEN & STEERS INC (CNS). This can be considered as Overvalued.


What is the profitability of CNS stock?

COHEN & STEERS INC (CNS) has a profitability rating of 7 / 10.


Can you provide the PE and PB ratios for CNS stock?

The Price/Earnings (PE) ratio for COHEN & STEERS INC (CNS) is 20.81 and the Price/Book (PB) ratio is 5.9.


What is the expected EPS growth for COHEN & STEERS INC (CNS) stock?

The Earnings per Share (EPS) of COHEN & STEERS INC (CNS) is expected to grow by 10.23% in the next year.